Press Releases - 2020-11-23

Date	Title	Company
23-Nov-2020	Demand for Insulin Delivery Pens to Experience a Significant Dip in 2020, Influenced by COVID-19 Pandemic	MARKITWIRED
23-Nov-2020	Competent Cells Market Forecast Revised in a New Future Market Insights Report as COVID-19 Projected to Hold a Massive Impact on Sales in 2020	MARKITWIRED
23-Nov-2020	COVID-19 to Have Significant Effect on Worldwide Adoption of Vital Signs Monitoring Devices in 2020	MARKITWIRED
23-Nov-2020	Future Market Insights Revises Oral Controlled Release Drug Delivery Technology Market Forecast, as COVID-19 Pandemic Continues to Expand Quickly	MARKITWIRED
23-Nov-2020	MRI – Compatible IV Infusion Pump Systems Market Revenue to Decline During Coronavirus Disruption, Stakeholders to Realign Their Growth Strategies	MARKITWIRED
23-Nov-2020	Oral Solid Dosage Pharmaceutical Formulation Market to Face a Significant Slowdown in 2020, as COVID-19 Sets a Negative Tone for Investors	MARKITWIRED
23-Nov-2020	Regional Outlook: Charcoal Facewash Market Is Expected To Grow with a Healthy CAGR During 2020-2027	Wired Release
23-Nov-2020	Oncology Information System Market To See Record Break Revenue $4.56 Billion by 2025, at CAGR of 7.1%	Wired Release
23-Nov-2020	Pain Management Devices Market Analysis Report, Reveals Lookout at Biggest Trends Hitting the Industry Over the upcoming 12 Months	Wired Release
23-Nov-2020	Relief Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AG	RELIEF THERAPEUTICS Holdings AG
23-Nov-2020	Juergen Ernst to retire from Pharming's Board of Supervisory Directors after more than 11 years of distinguished service	Pharming Group N.V.
23-Nov-2020	Juergen Ernst to retire from Pharming's Board of Supervisory Directors after more than 11 years of distinguished service	Pharming Group N.V.
23-Nov-2020	Creation of a research partnership between Pierre Fabre and Y-Biologics for the development of new immunotherapies based on monoclonal antibodies	Pierre Fabre and Y-Biologics
23-Nov-2020	Innovent Releases Phase 3 Results of TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Biosimilar Injection) as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC) at ESMO ASIA Virtual Congress 2020	Innovent Biologics, Inc.
23-Nov-2020	Innovent Releases Phase 3 Results of TYVYT(R) (Sintilimab Injection) in Combination with BYVASDA(R) (Bevacizumab Biosimilar Injection) as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC) at ESMO ASIA Virtual Congress 2020	Innovent Biologics, Inc.